| ¿µ¹® | testicular feminization syndrome | ÇÑ±Û | °íȯ¿©¼ºÈÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀÌÂ÷¼ºÀåÀ» Æ÷ÇÔÇÏ¿©, ¿Ü¼º±âÀÇ ¹ßÀ°Àº ¿©¼ºÀÌÁö¸¸ °íȯÀÌ Á¸ÀçÇϰí, Àڱðú ÀڱðüÀÌ °áÇ̵Ǿî ÀÖ´Â ³²¼º °ÅÁþ³²³àÇѸöÁõÀÇ ±Ø´ÜÀû ÇüÅÂÀÌ´Ù. À̰ÍÀº Å×½ºÅ佺Å×·ÐÀÇ ÀÛ¿ë¿¡ ´ëÇÑ ¸»´Ü±â°üÀÇ ÀúÇ׿¡ ±âÀÎÇÑ´Ù. |
||
| ¿µ¹® | irritable bowel syndrome | ÇÑ±Û | °ú¹Î¼º´ëÀåÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¹èº¯Àå¾Ö, º¹Åë, º¹ºÎÆØ¸¸ µîÀÇ Áõ»óÀÌ ÀÖÀ¸³ª ±âÁúÀûÀÎ º´º¯ÀÌ ¾øÀ½ÀÌ È®ÀÎµÈ ¿¹¸¦ ÃѸÁ¶óÇÑ ÀÓ»ó ÁõÈıºÀÌ´Ù. °¡Àå ÈçÇÑ ¼Òȱâ ÁúȯÀ̸ç(Àü¼Òȱâ ȯÀÚÀÇ 70~80%) °¡Àå ÈçÇÑ Áúº´(Àüü Àα¸ÀÇ ¾à 20%)ÀÌ´Ù. ¿©¼ºÀÌ ³²¼º¿¡ ºñÇØ 2¹è Á¤µµ ¸¹ÀÌ ¹ß»ýÇϸç 30´ë ¹× 40´ë¿¡¼ È£¹ßÇÏ°í ¼±Áø °ø¾÷±¹¿¡¼ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. Áø´ÜÀ» À§Çؼ´Â º´·Â ûÃë°¡ °¡Àå Áß¿äÇÏ°í °¢Á¾ °Ë»ç·Î¼ ±âÁúº´À» Á¦¿ÜÇØ¾ß ÇÑ´Ù. Ä¡·á·Î´Â ¾ÈÁ¤¿ä¹ý(Á¤½Å°úÀû ¸é´ã ¹× ½É¸®¿ä¹ý, ½Å°æ¾ÈÁ¤Á¦), ½Ä»ç¿ä¹ý(°í¼¶À¯Áú À½½Ä ¼·Ãë, Àڱؼº À½½Ä ÇÇÇϱâ), ¾à¹° ¿ä¹ý(âÀÚ°æ·Ã ÁøÁ¤Á¦, º¯ºñ ¿ÏÈÁ¦, Áö»çÁ¦) µîÀ» »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | withdrawal syndrome | ÇÑ±Û | ±Ý´ÜÁõÈı٠|
|---|---|---|---|
| ¼³¸í | ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀÌ´Â °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³´Ù. |
||
| ¿µ¹® | organic brain syndrome | ÇÑ±Û | ±âÁúÀû ³úÁõÈıº |
|---|---|---|---|
| ¼³¸í | ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇÏ´Â ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇÏ¸é ¾î¶² ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù´Â ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀÎ ÀÌ»ó¿¡ ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ ȯÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹¾î¼ ¸»ÇÑ´Ù. ÀÌ»ó¿¡ ÀÇÇØ ½Å°æÇÐÀûÀÎ ÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» Ⱦ¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀÎ ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Ư¡ÀûÀÎ Áõ»óÀº ¸ÕÀú, ÀǽÄÀÇ È¥Å¹ÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇÑ´Ù´Â °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀÎ ÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼ ¸»À» Ⱦ¼³¼ö¼³ÇÑ´Ù¸é, ÀÌ´Â ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù. |
||
| ¿µ¹® | Down syndrome | ÇÑ±Û | ´Ù¿îÁõÈıº |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ 46°³ ¿°»öü Áß Á¦ 21¹ø ¿°»öüÀÇ ¼ö°¡ 1°³ ´õ ¸¹¾ÆÁö¹Ç·Î½á ³ªÅ¸³ª´Â º´ÀÌ´Ù. ȯÀÚÀÇ »ý±è»õ°¡ ¸¶Ä¡ ¸ù°í »ç¶÷°ú ´à¾Ò´Ù ÇÏ¿© ÀÏ¸í ¸ù°íÁõ(mongolism)À̶ó°í ÇÏ¿´À¸³ª À߸øµÈ À̸§ÀÌ´Ù. ÀÌ º´Àº ¹Ýµå½Ã 21¹ø ¿°»öü°¡ 3°³°¡ µÇ´Â °æ¿ìÀ̿ܿ¡µµ 21¹ø ¿°»öüÀÇ ÀϺκÐÀÌ ´Ù¸¥ ¿°»öüÀÇ ÀϺκаú ±³È¯ÀÌ µÇ´Â translocationÇü µîÀÇ ´Ù¸¥ ¿°»öüÀ̻󿡼µµ º¼ ¼ö°¡ ÀÖ´Ù. ¹ß»ý ºóµµ´Â Ãâ»ý¾Æ 700~1000¸íÁß 1¸í ²Ã·Î ³ªÅ¸³ª¸ç, ¿°»öü ÀÌ»óº´ Áß¿¡ °¡Àå ¸¹Àº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ º´ÀÇ ¹ß»ýºóµµ´Â »ê¸ðÀÇ Ãâ»ê¿¬·É°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ¾î, 35¼¼ ÀÌÈİ¡ µÇ¸é ±âÇÏ ±Þ¼öÀûÀ¸·Î ÀÌ ÁúȯÀÚÀÇ Ãâ»ê¼ö°¡ Áõ°¡ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ Áúȯ¿¡ ÀÖ¾î¼ ¾à 3ºÐÀÇ 1Àº ¸ðÄ£ÀÇ Ãâ»ê¿¬·É¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ³ª¸ÓÁö ¾à 3ºÐÀÇ 2´Â ¸ðÄ£ÀÇ ¿¬·É°ú Á÷Á¢ °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°í ÀÖ´Ù. Áø´ÜÀº Ư¡ÀûÀÎ »ý±è»õ, Áï ¸ù°í »ç¶÷°°ÀÌ ´«²¿¸®°¡ À§·Î Ä¡ÄÑÁ® ÀÖ°í ´«°ÅÇ®ÀÌ µÎ²¨¿ì¸ç ÄàµîÀÌ ³·Àº Ư¡ÀûÀÎ ¾ó±¼ ¸ð½À, ¶ÇÇÑ ±ÙÀ°ÀÇ ±äÀåµµ°¡ ÀúÇϵǰí Á¥À» ºü´Â Èû°ú ¿ïÀ½ ¼Ò¸®°¡ ¾àÇÏ¸ç ¼Õ¹Ù´ÚÀÇ Á¿츦 °¡¸£´Â ÇÑÁÙÀÇ ¼Õ±Ý(¿ø¼þÀÌ¿Í °°Àº ÇüÅÂÀÌ´Ù) µîÀÇ Æ¯Â¡ÀûÀÎ ¼Ò°ß¿¡ ÀÇÇØ º¸Á¶Áø´ÜÀ» Çϰí ÃÖÁ¾ÀûÀ¸·Î ¿°»öü ºÐ¼®¿¡ ÀÇÇØ È®ÁøÀ» ÇÑ´Ù. ÀÌ ´Ù¿îÁõÈıºÀÇ È¯ÀÚ´Â ´ë°³ Áö´ÉÀÌ ÀúÇϵǾî ÀÖ°í, ¿©·¯ °¡Áö Á¾·ùÀÇ ¼±Ãµ¼º ½ÉÀå±âÇüÀ» ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖ´Ù. |
||
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
|---|---|
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
| PPS | Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc... |
| SBS | shaken baby syndrome; short bowel syndrome; sick building syndrome; sinobronchial syndrome; small bo... |
| DNIC | diffuse noxious inhibitory control |
|---|---|
| EIC | Elastase inhibitory capacity |
| XIP | Exchange-inhibitory peptide |
| FLIP | FLICE inhibitory protein |
| FIC | Fractional Inhibitory Concentration |
| macrophage migration-inhibitory factors | Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. (12 Dec 1998) |
|---|---|
| gastric inhibitory polypeptide | <hormone> Peptide hormone (43 amino acids) that stimulates insulin release and inhibits the release of gastric acid and pepsin. Acronym: GIP (18 Nov 1997) |
| G-protein, inhibitory GI | A g-protein that inhibits adenylyl cyclase and activates k+ channels. (12 Dec 1998) |
| migration-inhibitory factor | <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence. It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated. Acronym: MIF Synonym: inhibition factor. (22 Sep 2002) |
| migration-inhibitory factor test | A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced. Synonym: macrophage migration inhibition test, migration inhibition test. (05 Mar 2000) |
| minimal inhibitory concentration | <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro. (05 Mar 2000) |
| inhibitory | Of or pertaining to, or producing, inhibition; consisting in inhibition; tending or serving to inhibit; as, the inhibitory action of the pneumogastric on the respiratory center. "I would not have you consider these criticisms as inhibitory. <physiology> " (Lamb) Inhibitory nerves, those nerves which modify, inhibit, or suppress a motor or secretory act already in progress. Origin: LL. Inhibitorius: cf. F. Inhibitoire. Source: Websters Dictionary (01 Mar 1998) |
| inhibitory fibres | Nerve fibre's that inhibit the activity of the nerve cells with which they have synaptic connections, or of the effector tissue (smooth muscle, heart muscle, glands) in which they terminate. (05 Mar 2000) |
| inhibitory junction potential | Hyperpolarization of smooth muscle produced by stimulation of inhibitory nerves. (05 Mar 2000) |
| inhibitory-motor | <physiology> A term applied to certain nerve centers which govern or restrain subsidiary centers, from which motor impressions issue. Source: Websters Dictionary (01 Mar 1998) |
| inhibitory nerve | <anatomy, nerve> A nerve conveying impulses that diminish functional activity in a part. (05 Mar 2000) |
| inhibitory postsynaptic potential | The change in potential produced in the membrane of the next neuron when an impulse which has an inhibitory influence arrives at the synapse; it is a local change in the direction of hyperpolarization; the frequency of discharge of a given neuron is determined by the extent to which impulses that lead to excitatory postsynaptic potential's predominate over those that cause inhibitory postsynaptic potential's. (05 Mar 2000) |
| inhibitory synapse | A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell. The most common inhibitory neurotransmitter is GABA, this opens channels in the postsynaptic cell which tend to stabilise its resting potential, thus rendering it less likely to fire. See: excitatory synapse, presynaptic inhibition, postsynaptic inhibition. (18 Nov 1997) |
| Leukaemia inhibitory factor | <growth factor> Polypeptide growth factor or cytokine with wide range of activities. Regulates growth and differentiation of primordial germ cells and embryonic stem cells but has effects on peripheral neurons, osteoblasts, adipocytes and various cells of the myeloid lineage. Given to adult animals induces weight loss, behavioural disorders and bone abnormalities. Many of the effects of LIF in vitro can be mimicked by IL-6, oncostatin M and ciliary neurotrophic factor, all of which interact indirectly with gp130, a shared tranducer subunit. (18 Nov 1997) |
| leukocyte migration-inhibitory factors | Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat). (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|